Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ralph A DeFronzo

Showing results (21-30 of 355) with videos related to

Pageof 36
Sort By:
Diabetes Care|June 27, 2013
Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: The time has come for GLP-1 receptor agonists!Stanley Schwartz, Ralph A DeFronzo
Diabetes Care|October 31, 2009
Skeletal muscle insulin resistance is the primary defect in type 2 diabetesRalph A DeFronzo, Devjit Tripathy
Current Diabetes Reports|February 12, 2014
The use of non-insulin anti-diabetic agents to improve glycemia without hypoglycemia in the hospital setting: focus on incretinsStanley Schwartz, Ralph A DeFronzo
Cardiovascular Diabetology|August 7, 2009
Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body typeYoshinori Miyazaki, Ralph A DeFronzo
The Journal of Clinical Endocrinology and Metabolism|February 1, 2021
Insulin Resistance and Hyperinsulinemia: the Egg and the ChickenMuhammad Abdul-Ghani, Ralph A DeFronzo
Diabetes Care|April 29, 2011
Type 2 diabetes can be prevented with early pharmacological interventionRalph A DeFronzo, Muhammad Abdul-Ghani
Diabetes & Vascular Disease Research|May 1, 2007
The insulin resistance syndrome: physiological considerationsSangeeta R Kashyap, Ralph A Defronzo
Diabetes|July 15, 2025
Cushing Syndrome, Hypercortisolism, and Glucose Homeostasis: A ReviewRalph A DeFronzo, Richard J Auchus
Diabetes, Obesity & Metabolism|March 18, 2022
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetesRalph A DeFronzo, George L Bakris
The American Journal of Cardiology|August 2, 2011
Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucoseRalph A DeFronzo, Muhammad Abdul-Ghani
Pageof 36

Showing results (21-30 of 355) with videos related to

Sort By:
Pageof 36
Diabetes Care|June 27, 2013
Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: The time has come for GLP-1 receptor agonists!Stanley Schwartz, Ralph A DeFronzo
Diabetes Care|October 31, 2009
Skeletal muscle insulin resistance is the primary defect in type 2 diabetesRalph A DeFronzo, Devjit Tripathy
Current Diabetes Reports|February 12, 2014
The use of non-insulin anti-diabetic agents to improve glycemia without hypoglycemia in the hospital setting: focus on incretinsStanley Schwartz, Ralph A DeFronzo
Cardiovascular Diabetology|August 7, 2009
Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body typeYoshinori Miyazaki, Ralph A DeFronzo
The Journal of Clinical Endocrinology and Metabolism|February 1, 2021
Insulin Resistance and Hyperinsulinemia: the Egg and the ChickenMuhammad Abdul-Ghani, Ralph A DeFronzo
Diabetes Care|April 29, 2011
Type 2 diabetes can be prevented with early pharmacological interventionRalph A DeFronzo, Muhammad Abdul-Ghani
Diabetes & Vascular Disease Research|May 1, 2007
The insulin resistance syndrome: physiological considerationsSangeeta R Kashyap, Ralph A Defronzo
Diabetes|July 15, 2025
Cushing Syndrome, Hypercortisolism, and Glucose Homeostasis: A ReviewRalph A DeFronzo, Richard J Auchus
Diabetes, Obesity & Metabolism|March 18, 2022
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetesRalph A DeFronzo, George L Bakris
The American Journal of Cardiology|August 2, 2011
Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucoseRalph A DeFronzo, Muhammad Abdul-Ghani
Pageof 36